2型糖尿病患者非酒精性脂肪性肝病的管理:行动呼吁
本文综述2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)的管理,指出T2DM可加重NAFLD病程且肝病使糖尿病管理更复杂,NAFLD亦可见于非肥胖及无代谢综合征临床表型者;糖尿病似促进非酒精性脂肪性肝炎(NASH)发生并增加肝硬化与肝细胞癌风险;诊断与药物治疗存在不确定性,但近期诊疗进展与不作为的严重风险呼吁医疗提供者更积极主动管理T2DM与NASH患者。
要点
- T2DM可加重NAFLD病程,肝病亦使糖尿病管理更困难。
- NAFLD可见于非肥胖个体及无代谢综合征临床表现者。
- 糖尿病似促进NASH发生并增加肝硬化与肝细胞癌风险。
核心结论
- 近期诊断与治疗进展,加上不作为可致严重后果的风险,呼吁医疗提供者更积极主动管理T2DM与NASH患者。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- T2DM似加重NAFLD病程,而肝病使糖尿病管理更具挑战性,但二者关系本质仍未完全阐明。
- NAFLD患病率上升常归因于肥胖流行,常被简化为「代谢综合征的肝脏表现」,但实为更复杂疾病过程,亦可见于非肥胖个体及无代谢综合征临床表现者。
- 糖尿病似促进NASH这一更严重形式的發生,并增加肝硬化与肝细胞癌风险。
- 患者与医生面临诸多不确定性,包括疾病自然史信息碎片化、NASH诊断挑战及少有证实有效的药物。
临床怎么用
- 原文未据此给出具体推荐。
局限性
- 原文指出疾病自然史信息碎片化。
- 原文指出NASH诊断存在挑战。
- 原文指出少有证实有效的药物。
- 原文指出该关系本质仍未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the management of patients with T2DM and NASH.
引用
- Bril F, Cusi K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care. 2017. PMID: 28223446. doi:10.2337/dc16-1787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。